Pharmacogenetics Associated With IV Ketamine

Phase NA observational

Participants who previously received intravenous ketamine for treatment-resistant depression provide two saliva swabs for genetic analysis; the study examines associations between genetic markers and clinical response to IV ketamine.

Observational, prospective design leveraging clinic-treated patients at the Canadian Rapid Treatment Centre of Excellence; outcomes are biomarker–response correlations rather than interventional efficacy.

Canadian Rapid Treatment Centre of Excellence — Mississauga, Ontario, Canada

Inclusion Criteria:
1. Must have received IV ketamine previously to treat Treatment-Resistant Depression
2. Between the ages of 18-65 years old.
3. Clinical diagnosis of MDD
4. Individuals may have had comorbid psychiatric conditions (e.g., anxiety), but the comorbid psychiatric condition cannot be the primary clinical concern.
5. Ability to provide informed consent

Exclusion Criteria:
1. Individuals who meet DSM 5 criteria for a substance use and/or alcohol use disorder in the past 3 months.
2. Individuals who are currently experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent).
3. Individuals who are unable to consent to the procedure.
4. Individuals who are unable to adhere to the protocol in its totality

Start: 2021-01-01

End: 2021-01-08

Company

Product

Legal

Detailed Description

Study Arms & Interventions

Genetic samples

Interventions

Participants

Locations

Inclusion Criteria

Exclusion Criteria

Study Details

Study Team

Sponsors & Collaborators